New Frontiers in the Management of Hepatocellular Carcinoma (HCC): Exploring Novel Treatment Advances and Approaches
A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 17, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Eisai, and Exelixis

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. The prevalence and mortality rate of liver cancer has been rising steadily over the past decade and is still increasing as death rates are rising faster than any other type of cancer. Prognosis is especially poor for those with unresectable HCC. Fortunately, new agents have become available for the first time in almost 10 years, including targeted therapies such as Tyrosine Kinase Inhibitors (TKIs). These regimens have shown the ability to improve safety and efficacy outcomes, especially in patients with disease progression and may fulfill the unmet need of treatment, particularly beyond first-line setting.

Upon Completion of this activity, participants will be able to:

  • Analyze the safety and efficacy profiles of current and emerging immunotherapies or targeted therapies in the treatment of advanced hepatocellular carcinoma (HCC)

  • Discuss the relative benefits and limitations of immunotherapies for HCC beyond first-line therapy

  • Explore emerging clinical trial data on the use of biomarkers and immune checkpoint inhibitors in the management of HCC

  • Identify patients with HCC for whom an immunotherapy is an appropriate choice for the next step in the management of their cancer

  • Examine immune-related adverse events associated with the immunotherapies indicated for the treatment of patients with HCC in order to maximize tolerability and patient adherence

Faculty: David E. Kaplan, MD, MSc, FACP
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania


Dr. Kaplan previously received research or grant support from Bayer Healthcare. That relationship was terminated at least 12 months ago. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer Healthcare, Bristol-Myers Squibb, Eisai, and Exelixis

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue